Clinical Trial

A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This phase I study is designed to evaluate absorption, metabolism and excretion (AME) profiles of \[14C\]-DZD8586, to determine the routes, rates of elimination, and mass balance of DZD8586 in healthy adult male participants. Participants will be administered a single oral dose of 50 mg of \[14C\]-DZD8586 (containing radioactive dose \~ 100 μCi) as a suspension.
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Completed 2026-05-15
notable Primary completion moved earlier: 2026-08 -> 2026-03-27 2026-05-15
minor Completion moved earlier: 2026-09 -> 2026-04-06 2026-05-15
Trial Details
NCT Number NCT07454863
Lead Sponsor Dizal Pharmaceuticals
Conditions Lymphoma, Non-Hodgkin
Enrollment 6 participants
Start Date 2026-03-16
Primary Completion 2026-03-27 (estimated)
Study Completion 2026-04-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-14